| Forward Looking Statements2Statements in this presentation contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in thispresentation may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similarwords, and include, without limitation, all statements other than those regarding historical facts, statements regardingVirios Therapeutics, Inc.’s expectations regarding our futurefinancial or business performance, plans, prospects, trends or strategies, objectives of management, competition and other financial and business matters; the potential, safety,efficacy, and regulatory and clinical progress of our current and prospective product candidates, planned clinical trials and preclinical activities, and projected research anddevelopment costs; the estimated size of the market for our product candidates; and the timing and success of our development and commercialization of our anticipated productcandidates and the market acceptance thereof. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptionsthat are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These statements areneither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievementsto be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following:the outbreak of the novel coronavirus disease, COVID-19, has adverselyimpacted and may continue to adversely impact our business, including our preclinical studies and clinicaltrials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incursignificant losses; our need for additional funding, whichmay not be available; our substantial dependence on the success of our lead product candidates; failure to identifyadditional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials couldcause delays or other adverse consequences;risks relating to the regulatory approval process or ongoing regulatory obligations; our product candidates may cause seriousadverse side effects; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; ourability to attract, retain andmotivate qualified personnel; and significant costs as a result of operating as a public company. These and other risks and uncertainties are describedmore fully in the section titled “Risk Factors”in theAnnual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”)and elsewhere in our filings and reports with the SEC. While we may elect to update these forward-looking statements at some point in the future, we assume no obligation to updateor revise any forward-looking statements except to the extent required by applicable law. Although we believe the expectations reflected in such forward-looking statements arereasonable, we can giveno assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-lookingstatements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.This presentation also contains estimates and other statistical data made by independent parties and by us relating to marketsize and other data about our industry. This datainvolvesa number ofassumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimatesof our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Neither we nor ouraffiliates, advisors or representatives makes any representation as to the accuracy or completeness of that data or undertake to update such data after the date of this presentation.You should read the documents that we have filed with the SEC for more complete information about us. We encourage you to read such documents in full for more detailedinformation on statistics, reports and clinical trials referenced in this presentation.You may access these documentsfor free by visiting EDGAR on the SEC website athttp://www.sec.gov.Nasdaq: VIRI |
